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Abstract
Introduction
Critically ill hospitalized patients are at increased risk of infection so we assessed the immu-
nogenicity of 23-valent pneumococcal polysaccharide vaccine (PPSV23) administered
within six days of injury.
Methods
This prospective observational study compared the immunogenicity of PPSV23 among criti-
cally ill burn and neurosurgical patients at a tertiary, academic medical center. Patients
received PPSV23 vaccination within six days of ICU admission per standard of care. Con-
sent was obtained to measure concentrations of vaccine-specific IgG to 14 of 23 serotype
capsule-specific IgG in serum prior to and 14–35 days following PPSV23. A successful
immunologic response was defined as both a2-fold rise in capsule-specific IgG from base-
line and concentrations of >1 mcg/mL to 10 of 14 measured vaccine serotypes. Immuno-
logic response was compared between burn and neurosurgical patients. Multiple variable
regression methods were used to explore associations of clinical and laboratory parameters
to immunologic responses.
Results
Among the 16 burn and 27 neurosurgical patients enrolled, 87.5% and 40.7% generated a
successful response to the vaccine, respectively (p = 0.004). Both median post-PPSV23
IgG concentrations (7.79 [4.56–18.1] versus 2.93 [1.49–8.01] mcg/mL; p = 0.006) and fold
rises (10.66 [7.44–14.56] versus 3.48 [1.13–6.59]; p<0.001) were significantly greater in
burn compared with neurosurgical patients. Presence of burn injury was directly and days
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from injury to immunization were inversely correlated with successful immunologic response
(both p<0.03). Burn injury was associated with both increased median antibody levels post-
PPSV23 and fold rise to 14 vaccine serotypes (p<0.03), whereas absolute lymphocyte
count was inversely correlated with median antibody concentrations (p = 0.034).
Conclusion
Critically ill burn patients can generate successful responses to PPSV23 during acute injury
whereas responses among neurosurgical patients is comparatively blunted. Further study is
needed to elucidate the mechanisms of differential antigen responsiveness in these popula-
tions, including the role of acute stress responses, as well as the durability of these antibody
responses.
Introduction
Critically ill patients can exhibit profound inflammation and immunosuppression, and experi-
ence a high incidence of associated secondary infections [1]. Catastrophic injury and microbial
invasion elicit an acute inflammatory response, often followed by a primary or compensatory
anti-inflammatory response syndrome which can lead to an immunosuppressed state [1–6].
The presence of this proposed immunosuppressed state, which often accompanies sepsis,
burn, trauma, and neurologic injury, is largely based on measurements of local and systemic
immune parameters [2–8]. Such indirect measurements of immune function may not ade-
quately assess the patient’s ability to generate an integrated response to specific antigenic chal-
lenge, such as vaccination.
Vaccines provide a relevant probe of immune integrity [9,10] and protection against sec-
ondary infections. The utility and interpretation of vaccine responsiveness in the diagnosis of
immunodeficiency has been described by the American Academy of Allergy, Asthma and
Immunology as well as a Joint Task Force on Practice Parameters last updated in 2015 [9,10].
As a screening tool for suspected primary immunodeficiency, specific antibody deficiency can
be measured, in part, by IgG response to polysaccharide vaccines [10]. Immune function
dynamics may vary between critically ill populations, and within a population due to individ-
ual patient variables. Specifically, critically ill burn patients display an immune dysregulation
that often includes a down-regulation of immune signaling genes, decreased circulating den-
dritic cells, decreased monocyte human leukocyte antigen-DR, and derangements in cytokine
excretion [6, 11–15]. Similarly, the immune consequences of catastrophic neurologic injury
seen in ischemic and hemorrhagic stroke may be related to an impaired responsiveness of
monocytes, lymphopenia, a cholinergic neuro-linked immune reflex, as well as activation of
innate receptor signaling, e.g., by damage-associated molecular pattern pathways [16–21].
Thus, immune dysregulation following severe burn and stroke may contribute to the associ-
ated excessive morbidity and mortality [11, 12, 15, 16, 18] and affect the integrity of vaccine
responses.
The Center for Disease Control and Prevention’s Advisory Committee on Immunization
Practices recommends pneumococcal vaccination for all adults over 65 years of age and to
those 19–64 years old with a high-risk condition for invasive pneumococcal disease [22].
Previously, the Joint Commission and the Centers for Medicare and Medicaid Services recom-
mended core measure standards for accredited hospitals to improve coverage by administering
pneumococcal vaccines to indicated patients prior to discharge [23]. Thus, our institution
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implemented an interdisciplinary 23-valent pneumococcal polysaccharide vaccine (PPSV23)
protocol to encourage administration as early as possible, including to critically ill patients
[24]. To determine whether systemic insults (e.g., burn or neurologic trauma) affected vaccine
outcomes, we assessed the frequency and magnitude of pneumococcal serotype-specific anti-
body responses, and, in a subset of subjects, functional opsonophagocytic responses [25] to
PPSV23 when administered within six days of initial insult, and associated clinical variables
that may have affected these outcomes.
Methods
The aim of this prospective observational cohort study was to comparatively evaluate the
immunogenicity of PPSV23 in critically-ill burn and neurosurgical patients. We assessed
patient variables associated with immunogenicity. In addition, multiplexed opsonophagocyto-
sis assays (MOPA) were conducted as a feasibility pilot to assess antibody functionality. This
study was approved by the Colorado Multiple Institution Review Board (13–2435) and con-
ducted in accordance with board policies including prospective consent of participant or
proxy.
Patient enrollment
We prospectively enrolled 46 patients admitted to a burn or neurosurgical intensive care unit
(ICU) for emergent/severe burn or neurologic injuries. Inclusion criteria included an indica-
tion and active order for PPSV23, age 19–88 years, ability to provide consent (or a known and
present proxy), an expected ICU stay of at least 14 days, and an offending insult that had
occurred within 6 days of PPSV23 being ordered. Burn patients (n = 18) required a total body
surface area burn (TBSA) of 10% or greater (primary chemical, electrical and frostbite injuries
were not eligible). Neurosurgical patients (n = 28) required the initial insult to be either an
ischemic stroke, subarachnoid hemorrhage (SAH), intracranial/intraparenchymal hemorrhage
(ICH/IPH) or subdural hemorrhage (SDH). Exclusion criteria were refusal of PPSV23 admin-
istration, lack of consent to study, known immune deficiency (including previous organ or
bone marrow transplantation, HIV infection, active cancer or previous treatment with chemo-
therapy, and asplenia), primary admission for a planned intervention (such as skin grafting or
neurosurgical intervention) or known previous pneumococcal vaccination. Written informed
consent was obtained from the patient or their legal proxy if deemed appropriate by both the
attending physician and nurse with protocols approved by the Colorado Multiple Institution
Review Board.
Immunization and samples
Patients were immunized intramuscularly in the left deltoid with 0.5 mL PPSV23 (Merck &
Co., Inc.; Whitehouse Station, NJ), or in the right deltoid as required to avoid the location of
burn injury. Ten mL of blood were collected in late afternoon prior to vaccine administration
and 14–35 days following vaccination in serum separator tubes (BD; Franklin Lakes, NJ) from
an existing intravenous line. Serum separator tubes were inverted a minimum of five times,
allowed to clot in a vertical position for 30 minutes, and then centrifuged at 1300g for 20 min-
utes. Serum was removed and stored at -70˚ C until analyzed.
Laboratory analyses
Prior to PPSV23 administration, we measured levels of C-reactive protein (CRP) by immuno-
turbidmetry and cortisol by chemiluminescent immunoassay in the clinical laboratory of the
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University of Colorado Hospital. Levels of pneumococcal capsule-specific IgG to 14 pneumo-
coccal serotypes (1, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 12F, 14, 18C, 19F and 23F) were tested by quanti-
tative multi-analyte fluorescent detection method (Luminex, Luminex Corporation, Austin,
TX) by ARUP laboratories (Salt Lake City, UT) with appropriate controls [26, 27]. As reported
by ARUP, the lower limit of detection is 0.01 mcg/mL with inhibition by homologous sero-
types of more than 95% (except serotypes 9V and 9N) and inhibition by heterologous sero-
types of< 15% for all 14 measured serotypes. Correlation coefficients (r2) compared to ELISA
was>0.85 for tested serotypes [27]. Intra-assay and inter-assay precision were reported at
<20% and<30% coefficient of variation, respectively. Patients were informed of their specific
IgG results and encouraged to discuss with their primary physician.
To characterize the function of capsule-specific IgG, a subset of samples (31 total, 13
matched pre-post vaccination and 5 post only) were analyzed by multiplexed opsonophagocy-
tosis assay (MOPA) for serotypes 1, 3, 5, 7F, 6B, 14 and 23F at the University of Alabama-Bir-
mingham, as described [25]. Opsonic indices (OIs) by MOPA analysis were defined as the
reciprocal of the interpolated serum dilution that kills 50% of the pneumococcal serotype.
Samples that did not kill 50% of the bacteria at the lowest dilution tested were reported as four,
which was one-half the lowest dilution tested. Antibody potency (AP) was calculated by OI /
IgG concentration (mcg/mL) [28]. Log transformed IgG concentration vs OI and OI vs AP
were graphically inspected and analyzed for correlations.
Definitions and statistical methods
We defined capsule-specific IgG responses to PPSV23 in serum as a composite outcome that
reflects both a rise from baseline and absolute IgG concentration as previously recommended
[9, 29–31]. We defined a successful composite immunologic response for each subject as the
combination of a2-fold rise in capsule specific IgG from baseline and levels > 1 mcg/mL for
10 of 14 serotypes. We also analyzed the proportion of subjects with 1) IgG concentrations of
>1.3 mcg/mL for 10 of 14 serotypes following vaccination [9, 10, 32], or 2) fold rise from base-
line of>4 for 10 of 14 serotypes [9, 31, 33]. These additional immunologic outcomes of “con-
valescent” IgG concentrations and “fold” rise from baseline, respectively, were utilized to
assess agreement of interpretation based on alternative immunologic response definitions pre-
viously reported in the literature [9, 31–34]. A post-hoc analysis of immunologic response was
conducted by additional criteria to assess agreement as defined by Moberley, et al [35] and
Bonilla, et al [10]. Responsiveness was defined as absence of specific antibody deficiency (mild,
moderate, or severe) using the 14 measured serotypes as well as seven serotypes (1, 3, 5, 8, 9N,
7F, 12F) not included in the previous 7-valent pneumococcal conjugate vaccine (PCV-7) [10].
Immunologic response was compared between burn and neurosurgical critically ill patients.
Exploratory associations between clinical variables and immunogenicity were conducted in the
whole critically ill population (both burn and neurosurgical combined). Categorical variables
were analyzed by Fisher’s exact test. Continuous variables are reported as median with corre-
sponding interquartile range [(IQR)] or mean with corresponding standard deviation (SD). T-test
and Wilcoxon rank sum were utilized for comparisons between groups of normally distributed
and non-parametric data, respectively. We identified univariate associations at a p-value< 0.2
between clinical and laboratory variables and successful composite immunologic responses. A
multivariable logistic model was created from these significant variables by forward-step methods.
Variables associated with patient-specific median post-PPSV23 IgG concentrations and median
fold rise from baseline across all tested serotypes were assessed by forward-step linear regression
using a model entry criteria of p< 0.2. All tests were two-sided with p-values< 0.05 considered
significant and 95% confidence intervals (95% CI) reported.
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Results
Among 46 critically ill patients (18 burn and 28 neurosurgical patients) enrolled, three did not
complete the study due to early discharge in two (burn patients) and one death (neurosurgical
patient) before post-vaccination day 14. No severe adverse events related to PPSV23 were
reported. Fever developed within 72 hours of PPSV23 administration in three (19%) burn and
four (15%) neurosurgical patients. Six of the seven episodes were accompanied by culture posi-
tive infections (three respiratory, one blood, one urine, one skin). Clinically, the neurosurgical
patients were older and more severely ill than those with burns, with higher APACHE scores
and higher frequencies of the need for vasopressors and mechanical ventilation (Table 1). In
contrast, laboratory markers of inflammation (numbers of white cells and CRP) were higher
among burn patients.
Successful composite immunologic response frequencies were significantly higher among
patients with burns than among those with neurologic injuries (88% vs. 41%; p = 0.004) (Fig
1). This pattern of immunologic response was consistent when analyzed by the proportion of
subjects achieving an absolute “convalescent” concentration of capsule-specific IgG (94% vs
56%; p = 0.014) and fold rises (69% vs 26%; p = 0.01) in burn and neurosurgical patients after
vaccination, respectively. This was consistent among post-hoc assessments of immunologic
response favoring burn patients. Burn patients had an 81–94% response rate compared to a
33–41% response rate in neurosurgical patients depending on the post-hoc definition used
Table 1. Patient demographics.
Characteristic Burn (n = 16) Neurosurgical (n = 27) P-value
Gender (male), n (%) 10 (62.5) 13 (48.1) 0.53
Age, mean ± SD 40 ± 12 55.3 ± 13 <0.001
Ethnicity, n (%)
• Hispanic 3 (18.8) (22.2) —
• Caucasian 13 (81.2) 66.7)
• Black 0 (7.4)
• Other 0 1 (3.7)
Primary Diagnosis, n (%)
TBSA (mean ± SD): 23.9 ± 12.8 SAH: 19 (70) —
ICH: 3 (11)
SDH: 1 (4)
Ischemic: 4 (15)
APACHE II, mean score ± SD 11.9 ± 6.4 17.8 ± 7.2 0.01
ICU length of stay, median days [IQR] 25 [13–30] 24 [17–30] 0.9
Required vasopressors, n (%) 5 (31.3) 20 (74.1) 0.01
Required mechanical ventilation, n (%) 10 (62.5) 21 (77.8) 0.28
Days from admission to PPSV23 administration, mean ± SD 2.9±1.9 3.9 ± 2.2 0.13
Time from vaccination to follow-up blood draw, median days [IQR] 14 [14–14] 14 [14–14] 0.99
White blood cell counta (103 cells/mcL), mean ± SD 20.5 ± 8.7 14.6 ± 3.4 0.02
Total lymphocytesa (103 cells/mcL), mean ± SD 1.8 ± 1.19 1.3 ± 0.65 0.16
Cortisola (mcg/dL), mean ± SD 13.7 ± 7 17 ± 9.5 0.22
CRPa (mcg/dL), mean ± SD 16.2 ± 7.6 9.07 ± 6.8 0.005
TBSA, total burn surface area percent; SD, standard deviation; SAH, subarachnoid hemorrhage; ICH, intracerebral hemorrhage; SDH, subdural hemorrhage; PPSV23,
23-valent pneumococcal polysaccharide vaccine; IQR, interquartile range; CRP, C-reactive protein
a, values day of PPSV23 administration
https://doi.org/10.1371/journal.pone.0197037.t001
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(p<0.005 for all comparisons). There was relative agreement among outcomes when the com-
posite immunologic response and all three post-hoc definitions were compared with three or
less patients (<7%) being discordantly classified as responders or non-responders. All data is
available in Table A in S1 Table. Dataset PPSV23 in Critically-ill.
In addition to the increased frequencies of immunologic success, patients admitted with
burns also generated higher levels of capsule-specific IgG to 7 of 14 individual serotypes tested
(Table 2). Moreover, burns were also accompanied by significantly increased fold-rises to 9 of
14 serotypes following immunization, despite similar baseline prevaccination values. Re-
sponses to serotypes 3, 4, 6B, 8, 14, 18C and 23F were most often increased during burn injury.
Six of these 7 serotypes (all but type 8) are also included in the current 13-valent pneumococcal
conjugate vaccine (PCV-13; Prizer Vaccines) and its antecedent PCV-7, serotypes that are
most prominent in infants.
Variables associated with achieving immunologic success (p< 0.2) were considered for
multivariable logistic regression by forward-step modeling (Table 3). A comparison of charac-
teristics between patients achieving composite immunologic response and non-response is
reported in Table 4. Clinically, burn diagnosis directly was significant independent positive
predictor of immunologic success (Unit Odds 8.98, 95% CI 1.54–52.3, p = 0.015) as was days
Fig 1. Proportion of patients in the ICU with burn and neurologic injuries who achieved successful responses to 23-valent pneumococcal
polysaccharide vaccine. Proportion of response following 23-valent pneumococcal polysaccharide vaccine (PPSV23) by corresponding definition.
Composite Response Outcome: IgG concentration 1 mcg/mL and 2 fold increase from baseline (successful immunologic response). Convalescent IgG
Response Outcome: Post-vaccination IgG concentration of 1.3 mcg/mL. Fold-Rise Outcome: 4 fold increase from baseline. These definitions must
be met by 10 of 14 measured serotypes to be considered a responder. Error bars indicate 95% confidence interval. IgG, Immunoglobulin concentration
as microgram (mcg) per milliliter (mL).
https://doi.org/10.1371/journal.pone.0197037.g001
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between hospital admission a negative predictor of vaccine success (0.67, 95% CI 0.47–0.96,
p = 0.022), with the area under to response operator characteristic 0.82 (for both together).
Table 2. Burn versus neurosurgical comparisons of serotype specific IgG concentrations pre and post vaccination and fold increase.
Serotype Patient Population Pre PPSV23 (mcg/mL) P-value Post PPSV23 (mcg/mL) P-value Fold Increase (Post/Pre) P-value
1 Burn 0.38 [0.19–0.74] 0.38 6.06 [1.38–22.8] 0.156 14.31 [5.5–42.28] 0.077
Neurosurgical 0.71 [0.18–1.03] 2.32 [1.2–7.69] 6.38 [1–24]
3 Burn 0.54 [0.17–0.86] 0.97 2.37 [1.33–7.8] 0.006 7.03 [2.84–12.8] 0.002
Neurosurgical 0.46 [0.2–0.9] 0.77 [0.41–2.4] 1.83 [1.25–4.75]
4 Burn 0.25 [0.08–0.36] 0.44 2.69 [1.03–8.04] 0.001 21 [9.45–26.1] <0.001
Neurosurgical 0.24 [0.14–0.39] 0.59 [0.3–1.66] 1.88 [0.97–7.96]
5 Burn 6 [3.56–8.88] 0.91 16.7 [9.06–31.09] 0.135 3.8 [1.51–6.39] 0.051
Neurosurgical 6.9 [1.67–11.5] 10.7 [4.75–23.08] 1.39 [0.86–4.13]
6B Burn 0.48 [0.29–0.95] 0.16 7.32 [3.53–18.53] 0.025 13.85 [6.51–39] <0.001
Neurosurgical 0.85 [0.43–1.77] 2.33 [1–6.97] 1.92 [0.91–8.08]
7F Burn 0.99 [0.63–1.99] 0.51 6.94 [3.54–27.15] 0.085 9.93 [3.91–14.9] 0.011
Neurosurgical 1.23 [0.65–3.52] 4.27 [1.71–12.13] 1.61 [0.99–11.1]
8 Burn 0.75 [0.36–0.87] 0.61 9.81 [4.52–17.88] 0.006 13.01 [5.8–27.52] 0.006
Neurosurgical 0.95 [0.49–1.61] 4.04 [1.31–6.8] 2.62 [0.98–10.9]
9N Burn 0.2 [0.16–0.76] 0.44 2.49 [1.49–7.45] 0.285 10.07 [4.48–23.8] 0.063
Neurosurgical 0.37 [0.16–1.15] 1.75 [0.56–6.15] 3.56 [1.2–11.25]
9V Burn 0.65 [0.2–1.1] 0.17 12 [3.49–25.7] 0.145 18.99 [12.92–25] 0.003
Neurosurgical 0.8 [0.38–1.76] 5.47 [1.71–16.37] 5.95 [1.3–15.55]
12F Burn 0.65 [0.33–0.99] 0.45 1.11 [1.02–19.65] 0.443 3.46 [1.8–14.97] 0.209
Neurosurgical 0.33 [0.14–1.24] 1.39 [0.66–2.26] 2.17 [1.07–8.61]
14 Burn 0.53 [0.36–1.25] 0.014 24.8 [3.96–48.2] 0.037 33.2 [12.4–64.4] <0.001
Neurosurgical 1.47 [0.65–5.29] 8.22 [2.15–16.7] 2.09 [0.95–14.7]
18C Burn 3 [2.55–4.96] 0.67 32.8 [10.54–43.7] 0.004 10.72 [5.58–16.7] 0.003
Neurosurgical 2.46 [1–5.99] 6.88 [3.39–26.4] 3.35 [1.09–7.28]
19F Burn 2.75 [1.72–5.23] 0.8 19.9 [5.68–39.15] 0.061 4.16 [2.58–13.1] 0.085
Neurosurgical 3.41 [1.08–5.3] 7.92 [2.71–17.3] 2.98 [1–4.77]
23F Burn 0.53 [0.25–1.94] 0.71 17.5 [3.71–18.35] 0.002 12.86 [7.49–36.9] 0.001
Neurosurgical 0.62 [0.26–1.58] 2.64 [0.67–8.4] 2.52 [0.95–13.1]
All values reported as median [interquartile range]; IgG, immunoglobulin; PPSV23, 23-valent pneumococcal polysaccharide vaccine
https://doi.org/10.1371/journal.pone.0197037.t002
Table 3. Associations of successful composite immunologic response with clinical and laboratory variables.
Variable Univariate p-value Forward step model
Coefficient estimate (95% CI) p-value Unit Odds (95% CI)
Burn diagnosis 0.004 1.09 (0.22–1.98) 0.015 8.98 (1.54–52.3)
Days from admission to PPSV23 administration 0.01 -0.4 (-0.76–-0.04) 0.022 0.67 (0.47–0.96)
Age 0.02 Age, CRP, WBC, Hospital non-survivor, and APACHE II score did not meet
criteria to be significantly additive in association with the outcome of successful
composite immunologic response by forward step method (p >0.2 for each).
CRP 0.1
Highest WBC within 24 hours of admission 0.12
Hospital non-survivor 0.13
APACHE II score 0.15
PPSV23, 23-valent pneumococcal polysaccharide vaccine; CRP, C-reactive protein; WBC, white blood cell count; APACHE II, Acute Physiology and Chronic Health
Evaluation II
https://doi.org/10.1371/journal.pone.0197037.t003
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Forward-step multivariable linear regression modeling independently associated burn diag-
nosis with median post-PPSV23 IgG concentrations across all measured serotypes; whereas
the absolute lymphocyte count closest to PPSV23 administration was inversely associated with
median post-vaccine IgG concentrations. Days between hospital admission and vaccination,
requiring vasopressors, age and APACHE II values were not statistically significant predictors
of median post-PPSV23 IgG concentrations (Table 5). Only burn diagnosis was statistically
predictive of median fold rise from baseline.
Table 4. Comparison of patient characteristics by composite immunologic response.
Variable/Characteristic Responder (n = 25) Non-Responder (n = 18) p-value
Injury type —
• Burn, n (%) 14 (56) 2 (11) 0.004
• Neurologic, n (%) 11 (44) 16 (89)
Gender (male), n (%) 14 (56) 9 (50) 0.99
Age, mean ± SD 45 ± 13.8 56 ±14.1 0.02
Days from admission to PPSV23 administration, mean ± SD 2.76 ± 1.67 4.5 ± 2.3 0.01
APACHE II, mean score ± SD 14.2 ± 6.5 17.6 ± 8.2 0.15
Required vasopressors, n (%) 13 (52) 12 (67) 0.37
Required mechanical ventilation, n (%) 18 (72) 13 (72) 0.99
Highest white blood cell count within 24 hours of admission (103 cells/mcL), mean ± SD 18.2 ± 7.8 14.8 ± 3.4 0.12
White blood cell count at time of PPSV23 administration (103 cells/mcL), mean ± SD 11.2 ± 6.8 12.3 ± 5 0.55
Total lymphocytes at time of PPSV23 administration (103 cells/mcL), mean ± SD 1.33 ± 0.7 1.3 ± 0.6 0.87
Cortisol at time of PPSV23 administration (mcg/dL), mean ± SD 16 ± 8.5 15.5 ± 9.3 0.86
CRP at time of PPSV23 administration (mcg/dL), mean ± SD 13.3 ± 7.9 9.5 ± 7.4 0.1
Intensive care unit LOS, median [IQR] 25 [17.5–29.5] 22.5 [16.75–33.25] 0.7
Hospital LOS, median [IQR] 27[19–32] 30.5 [20.25–49] 0.54
Hospital non-survivor, n (%) 3 (12) 6 (33) 0.13
SD, standard deviation; PPSV23, 23-valent pneumococcal polysaccharide vaccine; CRP, C-reactive protein; LOS, length of stay; IQR, interquartile range
https://doi.org/10.1371/journal.pone.0197037.t004
Table 5. Multivariable forward-step linear regression model for median post-PPSV23 IgG concentration and IgG fold-rise from baseline.
Median post-PPSV23 IgG concentration Fold-rise in IgG from baseline
Variable Univariate Multivariable regression Variable Univariate Multivariable regression
p-value Coefficient (95% CI) p-value p-value Coefficient (95% CI) p-value
Burn diagnosis 0.006 2.29 (0.37–4.22) 0.02 Burn
diagnosis
<0.001 3.08 (1.4–4.75) <0.001
Absolute lymphocyte count
closest to PPSV23
administration
0.09 -3.13 (-6–-0.24) 0.034 CRP 0.031 NA >0.2
Days from admission to
PPSV23 administration
0.041 -0.74 (-1.63–0.15) 0.1 APACHE II
score
0.04 NA >0.2
Required vasopressors 0.052 NA >0.2 Required
vasopressors
0.1 NA >0.2
Age 0.1 NA >0.2 Highest
WBC within
24 hours of
admission
0.15 NA >0.2
APACHE II score 0.14 NA >0.2
PPSV23, 23-valent pneumococcal polysaccharide vaccine; CRP, C-reactive protein; NA, not applicable since the variable was not included in the final model; APACHE
II, Acute Physiology and Chronic Health Evaluation II
https://doi.org/10.1371/journal.pone.0197037.t005
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Fig 2. A) Log-transformed pneumococcal serotype-specific IgG vs Opsonic index, B) Log-transformed pneumococcal serotype-specific
Opsonic index vs antibody potency. A, Log transformed weak association of pneumococcal serotype (Pn ST) specific immunoglobulin (IgG)
concentrations and opsonic indices. B, Log transformed moderate association of pneumococcal serotype (Pn ST) specific opsonic indices and
antibody potency.
https://doi.org/10.1371/journal.pone.0197037.g002
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Multiplexed opsonophagocytosis assay (MOPA) results were confounded by the clinical
use of antibiotics in 20 of 31 planned samples. We report only results from 11 (4 obtained pre-
and 7 post-vaccination) antibiotic negative samples tested against 7 serotypes. All data is avail-
able in Table B in S1 Table. Dataset PPSV23 in Critically-ill. The concentrations of vaccine
capsule-specific IgG did appear to predict antibody function by MOPA. We found a consistent
correlation between specific levels and the ability of sera to opsonize the related organisms
overall (Opsonic Index; OI) and for 6 of 7 individual serotypes tested, particularly serotypes 1,
3, 5, and 23F (Fig 2A). Moreover, these OI’s also showed a significant correlation with the
Antibody Potency, which reflects the opsonic activity per microgram of capsule-specific anti-
body (Fig 2B). Specific values are reported in Table 6. Thus, in this subset of critically ill
patients, the antibodies produced in response to pneumococcal vaccination appear to demon-
strate the functional ability to opsonize the relevant pneumococcal organisms, suggesting their
potential to clear and kill these pathogens.
Discussion
Critically ill patients may experience an immunosuppressed state independent of or following
an inflammatory response to a physiologic insult [1–8, 16–18, 36, 37] and are at increased risk
for acute infections. We prospectively tested the ability of two distinct critically ill populations
in the ICU to respond to primary immunization (PPSV23) against a common cause of
Table 6. Pneumococcal antibody opsonic indicies and antibody potency in serum of three burn and eight neurosurgical serum samples.
Capsular Serotype Patient Population a Median OI Range OI Median Antibody Potency (OI/IgG) Range Antibody Potency (OI/IgG)
1 Burn Post-PPSV23 1292 496–1748 200 154–598
Neurosurgical Post-PPSV23 230 13–1657 47 8–200
Neurosurgical Pre-PPSV23 8 4–11 32 5–74
3 Burn Post-PPSV23 391 241–464 127 48–552
Neurosurgical Post-PPSV23 1033 431–1264 190 50–392
Neurosurgical Pre-PPSV23 73 28–116 127 35–240
5 Burn Post-PPSV23 1046 313–7109 191 15–290
Neurosurgical Post-PPSV23 201 13–381 21 16–31
Neurosurgical Pre-PPSV23 16 4–50 40 1–69
6B Burn Post-PPSV23 3427 901–6764 285 91–9395
Neurosurgical Post-PPSV23 2419 1245–26302 786 298–114357
Neurosurgical Pre-PPSV23 77 12–329 186 39–658
7F Burn Post-PPSV23 12358 11855–12779 1236 686–5444
Neurosurgical Post-PPSV23 15848 923–76009 1632 63–8244
Neurosurgical Pre-PPSV23 766 361–7245 1540 156–7875
14 Burn Post-PPSV23 11551 10491–24596 510 277–6244
Neurosurgical Post-PPSV23 3427 1402–37826 245 78–17594
Neurosurgical Pre-PPSV23 722 481–1254 1013 687–1326
23F Burn Post-PPSV23 1191 536–32242 412 67–1757
Neurosurgical Post-PPSV23 798 4–2968 187 10–223
Neurosurgical Pre-PPSV23 73 4–376 163 21–291
PPSV23, 23-valent pneumococcal polysaccharide vaccine; OI, Opsonic index (reciprocal of the interpolated serum dilution that kills 50% of the bacteria). For reporting
purposes, serum that killed less than 50% of the bacteria are reported as 4, which is one half the lowest dilution of the serum tested. IgG, Immunoglobulin concentration
as microgram per milliliter.
a, Three burn and four neurosurgical post PPSV23 samples and four neurosurgical pre PPSV23 samples were able to be analyzed due to the presence of anti-
pneumococcal antibiotics being detected in the remaining samples
https://doi.org/10.1371/journal.pone.0197037.t006
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pneumonia, S. pneumoniae soon after admission. We found that critically ill burn patients fre-
quently responded successfully to PPSV23. In contrast, critically ill neurosurgical patients had
a blunted response to PPSV23 when compared with burn patients. Burn injury, as opposed to
neurologic injury, was a common positive predictor of immunologic response in all multivari-
able analyses conducted. To our knowledge, immunologic response to PPSV23, as measured
by pneumococcal serotype specific IgG, has not been investigated in these populations.
The differences in both the frequencies and the magnitudes of these humoral responses in
these two populations may derive from differences in the severity of their illnesses and related
immune parameters. Critically ill burn patients are stressed, hyperinflammatory and exhibit
altered immune function compared with healthy controls, but their robust response to vaccine
antigens compared with the relative infrequency of response in the neurosurgical patients
deserves further exploration. Immune-dysfunction with brain injury and in neurosurgical crit-
ically ill patients also has been reported [7, 16–18]. Recent investigations suggest that immune
modulation occurs in the acute and subacute phase of brain injury following ischemic stroke
[18]. This maturation to an “exhausted immune phenotype” is consistent with a compensatory
anti-inflammatory response framework [3, 8, 18]. Although our population largely included
hemorrhagic injury as opposed to ischemic stroke, the inverse relationship between hospital
day of PPSV23 administration and immunologic response also suggests a transition from
inflammatory to immune-depressed phenotype in these patients. Whether differences in dif-
ferential injury-related immune dysfunction in burn and neurosurgical insults as may be
revealed by analyses of biomarkers, cytokines, pro-inflammatory and pro-resolution molecules
underlie the striking differences in both the frequency and magnitude of acute immunogenic-
ity are important areas for investigation.
In considering potential mechanisms and correlations of the differential responses to vac-
cine in these two populations, univariate associations were identified for age, APACHE II
score, CRP, hospital mortality, WBC count. However, these clinical and laboratory variables
were not independently predictive of immunologic success, whereas burn diagnosis and,
inversely, admission day of PPSV23 administration were. Previous work has shown even
advanced age does not preclude IgG response following PPSV23 compared to younger adults
[38–41]. Amongst the independent associations identified by linear regression models for
median concentrations of IgG post-PPSV23 administration and fold-rise from baseline, burn
diagnosis was the common predictor of a more successful immunologic response. Based on
these results, administration of PPSV23 in critically ill burn patients is reasonable. Other deter-
minants should be considered to optimize outcomes among neurosurgical patients admitted
with severe ischemic stroke or hemorrhagic conditions, such as timing of vaccine administra-
tion as responses were limited when given within six days of injury. Vaccine administration
may need to be withheld until the patient is stabilized for discharge in order to elicit adequate
immunogenicity. The role of the conjugated pneumococcal vaccine (PCV-13) to illicit immu-
nogenicity remains unknown in critically ill patients, but should be considered for future
study.
Logistically, we chose an immunologic success definition that incorporated both IgG value
and fold rise. This outcome aligned well with other alternative definitions (absolute IgG con-
centrations >1.3mcg/mL or >4 fold rise from baseline), tools advanced for diagnosis of
immune deficiencies and with establish laboratory standards [9, 10, 30–35]. As our primary
definition was not the same as all others [10, 35], we assessed response and agreement using
multiple definitions providing support to our overall interpretation. Further, we utilized 14 of
23 serotypes with a multiplex platform to represent immunogenicity. This test performance at
ARUP compared to ELISA has been published [26, 27, 29, 30, 42], nevertheless should be con-
sidered when comparing to other methods as differences in performance may exist [32, 43].
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Use of clinical diagnostic criteria may mitigate some risk of discordant characterization but
caution is warranted when comparing results of different methods [9, 10, 26, 29, 32, 42, 43].
Testing of sera for vaccine responses predominantly at day 14 post-PPSV23 may have pre-
cluded identifying delayed peak responses to the vaccine over the following weeks. However,
given the critical nature of our patient population, early sampling was implemented to avoid
dropout due to death or transfer to outside facilities upon stabilization. Future studies will
compare the pace of immune response in these potentially compromised populations.
Measuring pneumococcal sub-serotype IgG concentrations does not imply protection from
future invasive illness. Results with selected samples showed a consistent correlation between
capsule-specific IgG and opsonophagocytosis, a critical mechanism for clearing pneumococcal
infections but we caution against over interpretation. Multiple retrospective and case-control
studies confirm the protection afforded by PPSV23 against invasive pneumococcal disease
[39] but a direct correlation with specific antibody levels (or “protective levels”) and function
has not been established in any context [44, 45]. However, the potential impact of ineffective
vaccination due to hyporesponsiveness in the neurologically compromised and elderly patients
could result in increased rates of invasive pneumococcal disease in this at risk population.
Although nosocomial pneumococcal infections occur, the primary goal of vaccination is dura-
ble protection in those at high risk [45]. Early pneumonia, of which pneumococcus is a com-
mon pathogen, following severe neurologic injury is well established and unlikely to benefit
from immediate vaccination as preventative antibiotic therapy failed to prevent pneumonia
[46,47]. Similarly in burn patients with a 0.5–3% incidence, pneumococcal infections tend to
occur within the first week of injury [48,49]. Therefore, until additional data are known, vacci-
nation upon stabilization from critical illness should be considered. Of note, our sample size
limits our ability to draw firm conclusions about safety of PPSV23 in these populations even
though no significant events were noted. However, it is comparable in size to other vaccine
responsiveness studies in other populations such as recovered trauma patients who required
splenic artery embolization or solid organ transplant recipients [50, 51].
In summary, a statistically significant difference in PPSV23 immunogenicity was found
between critically ill burn and neurosurgical patients. To our knowledge this is the first obser-
vational study to assess immunogenicity of PPSV23 early after injury in critically ill burn and
neurosurgical patients. Our findings suggest early administration of PPSV23 in the neurosur-
gical population fails to produce a robust immunologic response.
Conclusion
Critically ill burn patients had a robust short term immunologic response following PPSV23
administration compared to the significantly blunted responses among critically ill neurosur-
gical patients. Further research into dysregulated immune pathways resulting in antigen non-
responsiveness in neurosurgical patients is needed. The role of acute stress responses, optimal
timing of PPSV23 administration, as well as the durability of immunogenicity in these distinct
populations should be explored. Although, PPSV23 appears safe in these critically ill patients, a
differential immunologic response based on underlying insult may occur.
Supporting information
S1 Table. Dataset PPSV23 in critically-ill. Inclusive data supporting analyses of immu-
nologic response (Table A) and multiplexed opsonophagocytosis assay output of interest
(Table B).
(PDF)
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